14:52 , Jun 29, 2018 |  BC Week In Review  |  Financial News

AbbVie Ventures, HealthCap lead Carisma's $53M series A

Macrophage immunotherapy company Carisma Therapeutics Inc. (Philadelphia, Pa.) raised $53 million in a series A round led by existing investors AbbVie Ventures and HealthCap. Existing investors IP Group plc (LSE:IPO), Penn Medicine and Grazia Equity,...
04:01 , Jun 27, 2018 |  BC Extra  |  Financial News

AbbVie Ventures, HealthCap lead Carisma's $53M series A

Macrophage immunotherapy company Carisma Therapeutics Inc. (Philadelphia, Pa.) raised $53 million in a series A round led by existing investors AbbVie Ventures and HealthCap. Existing investors IP Group plc (LSE:IPO), Penn Medicine and Grazia Equity,...
05:08 , Jun 16, 2017 |  BC Week In Review  |  Financial News

Carma raises venture funding

On June 12, Carma Therapeutics Inc. (Philadelphia, Pa.) raised an undisclosed amount in an "initial" round of financing co-led by AbbVie Ventures and HealthCap. Grazia Equity and IP Group plc (LSE:IPO) also participated. Carma is...
19:46 , Jun 12, 2017 |  BC Extra  |  Financial News

Carma raises venture funding

Carma Therapeutics Inc. (Philadelphia, Pa.) said it raised an undisclosed amount in an "initial" round of financing co-led by AbbVie Ventures and HealthCap. Grazia Equity and IP Group plc (LSE:IPO) also participated. The company, which...
13:17 , May 18, 2017 |  BC Innovations  |  Emerging Company Profile

Spreading Carma

Carma Therapeutics LLC is subverting macrophages’ tumor-promoting role by engineering in chimeric antigen receptors (CARs) to turn the phagocytic cells into agents that suppress the growth of solid tumors. The company is a translational play...
19:36 , Apr 13, 2017 |  BC Innovations  |  Translation in Brief

Eating cancer

With immuno-oncology companies increasingly looking beyond T cells to other immune cell types that could drive an antitumor response, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has hit on a new strategy for enlisting macrophages. Although the cells...